Pemphigus Vulgaris Market Report: Market Size & Forecast 2026

Pemphigus vulgaris is a chronic autoimmune disorder marked by painful blisters and erosions of the skin and mucous membranes, with global prevalence estimated between 0.1 and 1.0 per 100,000 persons. The global PV market, covering both diagnostic and therapeutic segments, was valued at approximately $0.583 billion in 2026, continuing an upward trajectory from prior-year levels in the $530 million to $551 million range. Revenue is predominantly treatment-driven, concentrated in systemic corticosteroids, steroid-sparing agents such as azathioprine and mycophenolate mofetil, intravenous immunoglobulin (IVIG), and a growing pipeline of biologic therapies that target specific autoantibody pathways.

• •2026 market value of approximately $583 million, up from roughly $530-551 million in 2025 depending on analytical scope and methodology
• •Therapeutics dominate the market, while diagnostics and supportive care constitute a smaller but necessary complementary segment
• •Disease rarity and orphan-drug designation frameworks significantly shape pricing dynamics, regulatory review timelines, and market access conditions

Rising clinical awareness of pemphigus vulgaris among dermatologists and immunologists is enabling earlier and more accurate diagnosis, effectively expanding the addressable treated patient population worldwide. Regulatory incentives, including orphan-drug status and fast-track pathways in major markets, are shortening development timelines, extending market exclusivity, and incentivizing investment in next-generation biologic agents. A concurrent shift from long-term high-dose corticosteroid regimens toward steroid-sparing targeted therapies is improving patient outcomes and supporting premium pricing tiers for newer products.

• •Orphan drug and breakthrough therapy designations in key regulatory jurisdictions reduce development timelines and confer extended market exclusivity periods
• •Clinical adoption of biologic alternatives to broad immunosuppression improves efficacy and safety profiles, supporting premium pricing and expanded utilization
• •Growth in subspecialty dermatology and immunology infrastructure in emerging economies is broadening patient access to advanced therapies

By treatment modality, the market segments into corticosteroids, conventional immunosuppressants, IVIG, biologics, and combination therapies, with biologics representing the fastest-growing sub-segment as more agents receive regulatory approval and clinical acceptance. North America holds the dominant global position, projected to reach approximately $376 million by 2032, supported by advanced healthcare infrastructure, high disease awareness, and favorable reimbursement policies. Europe is the second-largest region, valued at roughly $106 million in 2024 and projected to approach $169 million by 2030, while the Asia-Pacific region is emerging as a high-growth geography driven by rising healthcare expenditure and improving diagnostic and treatment access.

• •North America leads globally, with regional market size expected near $376 million by 2032 at a CAGR of approximately 8.9%
• •Europe, valued around $106 million in 2024, is forecast to grow to approximately $169 million by 2030, reflecting steady but more moderate expansion
• •Asia-Pacific and select Latin American markets are the fastest-growing secondary regions, propelled by healthcare infrastructure development and increasing specialist physician density

Who are the notable companies in the industry?

The competitive environment is moderately fragmented, comprising a mix of large diversified pharmaceutical enterprises with established immunology and dermatology portfolios and smaller specialty biopharmaceutical firms focused on autoimmune disease therapeutics. Integrated manufacturers that span active pharmaceutical ingredient production through finished dosage form compete alongside firms that specialize exclusively in biologic drug substance development and contract manufacturing services. Manufacturing routes are technically demanding: plasma-derived IVIG depends on large-scale human plasma fractionation and purification, while monoclonal antibody biologics require mammalian cell culture, sophisticated downstream processing, and cold-chain logistics. Production capacity is concentrated in North America and Western Europe, where regulatory requirements are most stringent and established biomanufacturing infrastructure is deepest, with incremental capacity additions occurring in select Asia-Pacific locations to serve domestic and regional demand.

• •Moderate fragmentation across a spectrum of integrated large-cap pharmaceutical producers and focused specialty biotech operators, creating competitive dynamics that balance scale advantages against therapeutic-area expertise
• •Dominant manufacturing routes include mammalian cell culture for recombinant monoclonal antibody biologics and large-scale fractionation for plasma-derived immunoglobulin products
• •Production and regulatory approval capacity is concentrated in North America and Europe, with a gradually expanding but still relatively limited presence in Asia-Pacific manufacturing jurisdictions

What are the recent trends and outlook?

The market is undergoing a structural transition from conventional broad immunosuppression toward targeted biologic therapies that selectively inhibit pathogenic autoantibody and B-cell activity, a shift expected to accelerate as more late-stage pipeline candidates receive approval. Biosimilar development for certain biologic agents may introduce pricing competition in the latter portion of the forecast window, though the small patient population and complex manufacturing requirements for these products will likely limit the pace of entry. Over the longer term, continued pipeline advancement, expanding approved indications, and improving global healthcare access are expected to sustain compound annual growth rates in the range of 7% to 8%, with several projections placing the broader market in the $1.1 billion range or higher by the early 2030s.

• •Biologic agents targeting B-cell and autoantibody pathways are projected to capture an increasing share of treatment protocols as late-stage clinical data matures and regulatory approvals accumulate
• •Biosimilar competition for established biologic therapies may moderate pricing pressure in the mid-to-late forecast period, though entry barriers remain significant given small patient populations
• •Long-term market projections from multiple sources converge toward $1.1 billion or higher by the early 2030s, reflecting baseline growth sustained by pipeline innovation and expanding geographic access